Implantable devices for chemonucleolysis of intervertebral discs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-047/32
A61L-027/54
A61K-047/34
A61F-002/44
A61F-002/30
출원번호
US-0605815
(2006-11-29)
등록번호
US-9061064
(2015-06-23)
발명자
/ 주소
Trieu, Hai H.
출원인 / 주소
Warsaw Orthopedic, Inc.
대리인 / 주소
Sorell Lenna & Schmidt LLP
인용정보
피인용 횟수 :
0인용 특허 :
36
초록▼
Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can al
Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also comprise one or more binders. The device can be an elongate solid body having a tapered or rounded insertion end. Alternatively, the device can include a plurality of particles.
대표청구항▼
1. An intervertebral disc implant comprising a chemonucleolysis agent in solid powder form, a plurality of particles and a binder, wherein the implant has a solid body throughout the cross-section of the implant and when placed into the nucleus pulposus of an intervertebral disc, the implant having
1. An intervertebral disc implant comprising a chemonucleolysis agent in solid powder form, a plurality of particles and a binder, wherein the implant has a solid body throughout the cross-section of the implant and when placed into the nucleus pulposus of an intervertebral disc, the implant having a sheath comprising the chemonucleolysis agent incorporated into the sheath, the implant sustainably releases the chemonucleolysis agent into the nuclear disc tissue surrounding the implant to proteolytically degrade the tissue, the chemonucleolysis agent comprises chymopapain and is incorporated into the particles. 2. The intervertebral disc implant of claim 1, wherein the particles have an average diameter of 0.1 to 500 μm. 3. The intervertebral disc implant of claim 1, wherein the particles have an average diameter of 0.5 to 250 μm. 4. The intervertebral disc implant of claim 1, wherein the particles have an average diameter of 1 to 100 μm. 5. The intervertebral disc implant of claim 1, wherein the chemonucleolysis agent further comprises collagenase, chondroitinase-ABC and human proteolytic enzymes. 6. The intervertebral disc implant of claim 1, wherein the solid body is an elongate solid body. 7. The intervertebral disc implant of claim 1, wherein the solid body is an elongate solid body having a tapered or rounded end. 8. The intervertebral disc implant of claim 1, wherein the solid body is a microsphere. 9. The intervertebral disc implant of claim 1, wherein the solid body has a profile shape selected from the group consisting of the profile shapes depicted in FIGS. 16A, 16B, 16C, 16D, 16E, 16F, 16G, 16H, 16I, 16J, 16K, 16L, 16M, 16N and 16O. 10. The intervertebral disc implant of claim 1, wherein the solid body has a circular cross section. 11. The intervertebral disc implant of claim 1, wherein the implant comprises up to 90% by volume of the binder. 12. The intervertebral disc implant of claim 1, wherein the implant comprises from 25 to 75% by volume of the binder. 13. The intervertebral disc implant of claim 1, wherein the binder is a polymer. 14. The intervertebral disc implant of claim 1, wherein the binder is a non-resorbable polymer, a bioresorbable polymer, or a naturally occurring polymer. 15. The intervertebral disc implant of claim 1, wherein the binder is a non-resorbable polymer selected from the group consisting of polyurethanes, polysiloxanes, polymethyl methacrylate, polyethylene, polyvinyl alcohol, polyvinyl pyrrolidone, poly(2-hydroxy ethyl methacrylate), polyacrylic acid, poly(ethylene-co-vinyl acetate), polyethylene glycol, polymethacrylic acid, and polyacrylamide. 16. The intervertebral disc implant of claim 1, wherein the binder is a bioresorbable polymer selected from the group consisting of polylactides, polyglycolides, polylactide-co-glycolides, polyanhydrides, and polyorthoesters. 17. The intervertebral disc implant of claim 1, wherein the binder is a naturally occurring polymer selected from the group consisting of polysaccharides, collagens, silk, elastin, keratin, albumin, and fibrin. 18. The intervertebral disc implant of claim 1, wherein the implant further comprises a second active agent different than the chemonucleolysis agent. 19. The intervertebral disc implant of claim 18, wherein the second active agent is a pain medication or a growth factor. 20. The intervertebral disc implant of claim 18, wherein the second active agent is a pain medication selected from the group consisting of codeine, propoxyphene, hydrocodone, and oxycodone. 21. The intervertebral disc implant of claim 18, wherein the second active agent is a growth factor selected from the group consisting of a transforming growth factor-B protein, a bone morphogenetic protein, a fibroblast growth factor, a platelet-derived growth factor, and an insulin-like growth factor. 22. The implant of claim 1, wherein the solid body further comprises a hydrogel coating. 23. The implant of claim 1, further comprising an x-ray marker. 24. The implant of claim 23, wherein the x-ray marker is a bead or a thread. 25. The implant of claim 23, wherein the x-ray marker comprises barium sulfate, platinum or tantalum. 26. The implant of claim 6, wherein the elongate solid body has no cross-sectional area with a maximum dimension greater than 5 mm. 27. The implant of claim 6, wherein the elongate solid body has no cross-sectional area with a maximum dimension greater than 3 mm. 28. The implant of claim 6, wherein the elongate solid body has no cross-sectional area with a maximum dimension greater than 1 mm. 29. The implant of claim 1, wherein the implant erodes upon resorption.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (36)
Froning Edward C. (215 N. San Mateo Drive San Mateo CA 94403), Apparatus and method for stereotaxic lateral extradural disc puncture.
Balaban Stephen M. (Chesterfield MO) Pike James B. (St. Peters MO) Smith Jonathan P. (St. Louis MO) Baile Clifton A. (Chesterfield MO), Delivery devices with pulsatile effect.
Santini, Jr., John T.; Cima, Michael J.; Langer, Robert S.; Ausiello, Dennis; Sheppard, Jr., Norman F.; Herman, Stephen J., Flexible microchip devices for ophthalmic and other applications.
Hudgin Donald Edward (Princeton Junction NJ) Blair Edgar Allan (Cranbury NJ), Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles.
Uhland, Scott A.; Polito, Benjamin F.; Herman, Stephen J.; Santini, Jr., John T.; Maloney, John M., Methods for hermetically sealing microchip reservoir devices.
John T. Santini, Jr. ; Charles E. Hutchinson ; Scott A. Uhland ; Michael J. Cima ; Robert S. Langer ; Dennis Ausiello, Microfabricated devices for the delivery of molecules into a carrier fluid.
Santini, Jr., John T.; Hutchinson, Charles E.; Uhland, Scott A.; Cima, Michael J.; Langer, Robert S.; Ausiello, Dennis, Microfabricated devices for the delivery of molecules into a carrier fluid.
Santini, Jr., John T.; Sheppard, Jr., Norman F.; Young, Chung Chang; Langer, Robert S., Microfabricated devices for the storage and selective exposure of chemicals and devices.
Santini, Jr., John T.; Sheppard, Jr., Norman F.; Young, Chung Chang; Langer, Robert S., Microfabricated devices for the storage and selective exposure of chemicals and devices.
Barrett Alan J. (Cambridgeshire GBX) Buttle David J. (Cambridgeshire WI GBX) Rich Daniel H. (Madison WI), Pharmaceutical composition of purified chymopapain.
Berry Dale T. ; Herald Coy M. ; Bates Brian L. ; Boatman Scott E. ; Hoffa Michael C. ; Fearnot Neal E. ; Voorhees ; III William D., Radially expandable stent.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.